Where are the adcomms? FDA has scheduled no drug or biologic meetings for 2024 so far
The FDA’s advisory committees of outside experts typically review controversial drug approval decisions at meetings scheduled months in advance. But the agency’s adcomm calendar for 2024 has yet to register a single meeting for either a drug or a biologic in 2024.
The FDA, which held three adcomms in January 2023 for drugs or biologics, did not immediately explain if the lag in the calendar was due to an internal change or just the result of the current PDUFA calendar.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
